We have created our first cancer drug candidate – a single-disease specific immunotherapy targeting Ewing sarcoma, a rare but deadly bone and soft tissue cancer primarily affecting children and young adults. Unfortunately, the death rate for patients with recurrent Ewing sarcoma is nearly 100%.
Based on the positive data, we may launch FDA IND enabling studies needed to apply for approval to proceed with human trials. We look forward to the day when treating cancer will be as simple as getting a flu shot – a better way to treat cancer.
According to Precedence Research, the global biotechnology market is projected to grow from $1.3 trillion in 2023 to $3.2 trillion by 2030
According to Fortune Business Insights, the global oncology drugs market is projected to grow from $205 billion in 2023 to $484 billion by 2030.
Our team of dedicated scientists is on the cutting edge of cancer research. From the lab to the clinic, we are committed to finding new and better ways to prevent and treat cancer.
Years of collective
experience
CancerVax, Inc., developer of a breakthrough Universal Cancer Treatment that will use the body’s immune system to fight cancer, today announced that its Reg A+ offering has been qualified by the SEC allowing the Company to formally launch a funding round of up to $5 million. Proceeds from the SEC qualified Reg A+ offering will be used by the Company to continue work on its breakthrough cancer treatments
CancerVax, Inc., developer of a breakthrough universal cancer treatment that uses the body’s immune system to fight cancer, today announced that in a recent Company podcast its CEO, Ryan Davies, and Tempus Labs Chief Medical Officer for Oncology Dr. Ezra Cohen, discussed his time at Tempus Labs, Moores Cancer Center and University of Chicago
CancerVax, Inc., a pre-clinical biotechnology company working with UCLA to develop breakthrough immunotherapy cancer treatments that use the body’s immune system to fight cancer, today announced an expansion of its development pipeline to include a Universal CAR-T Cell Platform that can dramatically lower the cost of CAR-T cell cancer therapies
CancerVax, Inc., developer of a breakthrough universal cancer treatment that uses the body’s immune system to fight cancer, today announced that in a recent Company podcast its CEO, Ryan Davies, spoke with and UCLA cancer physician and researcher, Dr. Steven Jonas, about his journey to becoming both a practicing cancer doctor and active cancer researcher